Development and clinical application of new liquid biopsy method in nasopharyngeal carcinoma
Project/Area Number |
15K20190
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Otorhinolaryngology
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 上咽頭癌 / Epstein-Barr virus / miRNA / バイオマーカー / BART / biomarker / miR-BART17-5p / nasopharyngeal carcinoma |
Outline of Final Research Achievements |
Epstein-Barr virus (EBV) -related RNA in serum was quantified using serum from 31 patients with nasopharyngeal carcinoma. We examined three BamHI A rightward transcripts (BART) miRNAs among BART miRNAs which are EBV-related RNA this time. As a result of comparing the quantitative results with the stage and recurrence of nasopharyngeal carcinoma patients, it was found that miR-BART17-5p reflects the prognosis of patients with nasopharyngeal carcinoma after treatment most.
|
Report
(3 results)
Research Products
(6 results)